Accès ouvert déclaré 2021 article

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Andrés J.M. Ferreri, Teresa Calimeri, Paolo Lopedote, Ilaria Francaviglia, Rita Daverio, Chiara Iacona, Cristina Belloni, Alessandro Gulino, Elena Anghileri, Angelo Diffidenti, Annamaria Finardi, Filippo Gagliardi, Nicoletta Anzalone, Alessandro Nonis, Roberto Furlan, Daniela De Lorenzo, Maria Rosa Terreni, Vittorio Martinelli, Marianna Sassone, Marco Foppoli, Piera Angelillo, Elena Guggiari, Andrea Falini, Pietro Mortini, Massimo Filippi, Vittoria Tarantino, Marica Eoli, Fabio Ciceri, Claudio Doglioni, Claudio Tripodo, Massimo Locatelli, Maria Giulia Cangi, Maurilio Ponzoni

96Citations signalées, ce qui n’est pas une note de qualité

6Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref: <i>MYD88</i> L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study
Date Crossref: 23/02/2021
Éditeur: Wiley
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la notice
Établissement de santé
Vita-Salute San Raffaele University pays non établi dans la notice
Université ou école supérieure
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele pays non établi dans la notice
Établissement de santé
University of Palermo Department of Health Sciences pays non établi dans la notice
Université ou école supérieure
Fondazione IRCCS Istituto Neurologico Carlo Besta pays non établi dans la notice
Établissement de santé
IRCCS Ospedale San Raffaele pays non établi dans la notice
Établissement de santé
Lymphoma Unit Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute Milan Italy Lymphoma Unit pays non établi dans la notice
Structure de recherche
Pathology Unit IRCCS San Raffaele Scientific Institute Milan Italy Pathology Unit pays non établi dans la notice
Structure de recherche
Division of Lab Medicine IRCCS San Raffaele Scientific Institute Milan Italy pays non établi dans la notice
Structure de recherche
Molecular Neuro‐Oncology Unit IRCCS Istituto Neurologico Carlo Besta Milan Italy pays non établi dans la notice
Institution
Molecular Neuro-Oncology Unit pays non établi dans la notice
Institution
Clinical Neuroimmunology Unit IRCCS San Raffaele Scientific Institute Milan Italy pays non établi dans la notice
Structure de recherche

Istituti di Ricovero e Cura a Carattere Scientifico, Vita-Salute San Raffaele University et Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

CNS Lymphoma Diagnosis and TreatmentLymphoma Diagnosis and TreatmentGlioma Diagnosis and Treatment

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI